Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M in HBV-related HCC
NCT06961617Phase 1Recruiting
- Sponsor
- Lion TCR
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by Lion TCR. Primary endpoints: Adverse Events and Objective Response Rate up to 2 years. Started Jun 2024; status: recruiting.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06961617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961617.